Topoisomerases are ubiquitous enzymes necessary for controlling the interlinking and twisting of DNA molecules. Among the four topoisomerases identified in eubacteria, two, DNA gyrase and topoisomerase IV, have been exploited by nature and the pharmaceutical industry as antibacterial targets. Natural products that are inhibitors of one or both of these topoisomerases include the coumarin and cyclothialidine classes, which interfere with adenosine triphosphate hydrolysis, cinodine, flavones, and terpenoid derivatives. The plasmid-encoded bacterial peptides microcin B17 and CcdB also inhibit DNA gyrase. The quinolones, a synthetic class of antibacterials that act on both DNA gyrase and topoisomerase IV, have had the broadest clinical applications, however. Quinolone congeners differ in their relative potencies for DNA gyrase and topoisomerase IV. Studies of an expanding set of resistant mutant enzymes and the crystal structure of the homologous enzyme in yeast have contributed to our understanding of interactions of these drugs with topoisomerase-DNA complexes and the ways in which mutations effect resistance.
The Topoisomerase Class of Enzymes
E. coli DNA gyrase (also referred to as topoisomerase II) and topoisomerase IV, break both strands of duplex DNA, pass Topoisomerases were first recognized with the discovery another DNA duplex through the break, and reseal both breaks in 1971 by James Wang of topoisomerase I, an enzyme of coordinately. Within these mechanistic classes, each enzyme Escherichia coli that was characterized by its ability to remove has distinct biochemical properties and apparent physiological negative superhelical twists from bacterial DNA [1] . There roles, although the activities of one enzyme may in special have recently been extensive reviews of this class of enzymes circumstances complement defects in another [6 -8] . [2, 3] . The class is defined by the common ability of the memIn the case of the type I topoisomerases, both topoisomerase ber enzymes to alter the topological state of DNA by the break-I and topoisomerase III are active as dimers consisting of a ing and passing of DNA strands.
single type of subunit encoded by the topA and topB genes, Since the discovery of topoisomerase I, three other topoisomrespectively [9 -16] . Topoisomerase I removes negative but not erases in E. coli have been identified, and members of this positive superhelical twists from circular DNA and functions in class also have been found in all bacteria in which they have the bacterial cell to oppose the actions of DNA gyrase and to been looked for. With the recent sequencing of two complete regulate the level of DNA supercoiling [17 -20] . Mutants with bacterial genomes, there is available for the first time a comtopA deletions accumulate reduced-function mutations in DNA plete overview of the genes encoding putative topoisomerases gyrase [21] or mutations causing hyperexpression of topoisomin an organism. On the basis of homology with the deduced erase IV [7, 22] that reduce excessive DNA supercoiling. Topoamino acid sequences encoded by the genes of E. coli topoisomerase III can also remove negative supertwists from circuisomerases, the smallest known genome for a free-living organlar DNA, but it has little involvement in the regulation of DNA ism, that of Mycoplasma genitalium [4] , encodes three toposupercoiling in vivo [16, 23] . isomerases, and the larger genome of Haemophilus influenzae Both topoisomerase I and topoisomerase III have the ability encodes four and possibly as many as five such enzymes [5] .
to unlink or decatenate interlocked DNA circles in which at The four known topoisomerases of E. coli can be classified least one member of the pair has a single-strand break or gap. into two groups based on mechanisms of action (table 1) . Type Topoisomerase III, however, functions in vitro in DNA replica-I topoisomerases, represented by E. coli topoisomerase I and tion systems as a decatenase, whereas topoisomerase I does topoisomerase III, break single strands of duplex DNA, pass not [24] . Topoisomerase III appears to be involved in the stabianother single DNA strand through the break, and then reseal lization of the bacterial genome, because topB deletion mutants, the break. In contrast, type II topoisomerases, represented by although viable, have increased rates of spontaneous deletions of chromosomal DNA [6, 15, 25] Both of the type II topoisomerases of E. coli are essential superhelical twists in vitro but is particularly efficient at removing interlocked or catenated DNA circles at the expense of for cell survival, as evidenced by the existence of conditional lethal mutations in their genes [7, 26 -28] . DNA gyrase is the ATP hydrolysis [8, 39] . Although DNA gyrase can be shown to have similar activity in vitro, it is a much less efficient only enzyme capable of introducing negative superhelical twists into bacterial DNA [29, 30] . The opposing actions of decatenase than is topoisomerase IV. Within the bacterial cell, topoisomerase IV appears to be DNA gyrase and topoisomerase I are key for maintaining and adjusting levels of DNA superhelical density within the bactethe principal enzyme that resolves interlocked daughter DNA circles occurring at the completion of a round of DNA replicarial cell [18, 20, 29 -32] , a homeostasis effected at least in part by the supercoiling-dependent expression of their genes [17, tion, allowing segregation of daughter chromosomes into daughter cells [40, 41] . Under special circumstances, hyperex-19, 33].
Introduction of superhelical twists by DNA gyrase occurs pression of DNA gyrase may complement defects in topoisomerase IV [8] , and hyperexpression of topoisomerase IV may at the expense of adenosine triphosphate (ATP) hydrolysis. However, this enzyme can also remove negative as well as complement defects in topoisomerase I [7] . positive superhelical twists. Positive superhelical twists accumulate ahead of the DNA replication fork [2, 34] 
and in areas
Topoisomerases as Antibacterial Targets of gene transcription by RNA polymerase [6, 35 -38] , particularly for those genes in which the nascent RNA chain may be Because of their presumed presence in all bacteria and in some cases their essential roles within the bacterial cell, toporotationally constrained because of concurrent coupled translation of a protein product that is inserted into the cell membrane.
isomerases are appealing targets for antibacterial therapy, and both nature and the pharmaceutical industry have been success-DNA gyrase appears to be the enzyme removing the accumulated positive supercoils that might otherwise impede replicaful in exploiting them for this purpose. Both natural and synthetic compounds have been shown to inhibit DNA gyrase tion or transcription [2, 34] , although a role for topoisomerase IV has not been excluded entirely.
and to exhibit antibacterial activity. At least some of these compounds also inhibit topoisomerase IV. Antagonists of topoTopoisomerase IV is the most recently discovered E. coli topoisomerase. It is similar in structure to DNA gyrase. Both isomerase I and topoisomerase III have been less explored, and it is only the inhibitors of DNA gyrase and more recently enzymes are tetramers composed of pairs of two types of subunits. The GyrA and GyrB subunits of DNA gyrase (encoded topoisomerase IV that have been developed as antibacterial agents. My discussion will thus focus largely on inhibitors of by gyrA and gyrB, respectively) are similar in amino acid sequence to the ParC and ParE subunits (encoded by parC and DNA gyrase and topoisomerase IV. Novobiocin, coumermycin A1, and clorobiocin are coumaparE) of topoisomerase IV, respectively [8, 39] . Specifically, 36% of the amino acids of ParC are identical to those of GyrA, rins that are natural products of Streptomyces species. Novobiocin was developed as an antibacterial agent before its target and 40% of the amino acids of ParE are identical to those of GyrB [7] .
enzyme DNA gyrase was known. These coumarins have been shown to inhibit the ATPase activity of DNA gyrase that is Particularly conserved between GyrA and ParC is the amino acid sequence in the amino terminus of the enzyme, a region necessary for catalytic enzyme turnover, and novobiocin treatment of susceptible bacteria results in reduced DNA supercoilthat contains the tyrosine residues in the active sites of the enzymes. Topoisomerase IV can remove negative and positive ing [42 -47] . The ATPase activity of DNA gyrase is mediated by the GyrB congeners have been shown to have selective activity against topoisomerase IV [56] . Flavones have generally had limited subunit, and the x-ray crystallographic structures of a GyrB fragment with a bound ATP analog and with bound novobiocin antibacterial activity, presumably because of limited permeation into the bacterial cell, and flavone-resistant bacterial muhave shown that the nucleotide and the inhibitor have incompletely overlapping binding sites on GyrB, providing a structants have not been reported. Flavones may also have toxicities related to their activity against eukaryotic topoisomerase II tural basis for understanding the competitive inhibition of this class of compounds [44 -47] . Mutations in gyrB that confer [57, 58] . The terpenoid derivatives clerocidin, terpentecin, and resistance to coumarins alter amino acids involved in the drug binding site deduced from the crystal structure.
UCT4B are natural products of the fungi -Oidiodendron and Kitasatosporia species -that inhibit bacterial DNA synthesis It is interesting that Streptomyces sphaeroides, the organism producing novobiocin, contains genes for drug-susceptible and [59] . Clerocidin has also been shown to inhibit DNA supercoiling by purified DNA gyrase and to stabilize a DNA-cleavage drug-resistant GyrB subunits and preferentially expresses the drug-resistant GyrB subunit in response to the reduced DNA complex in vitro [60] . In addition, quinolone-resistant gyrA mutants were cross-resistant to clerocidin, and mutants selected supercoiling occurring in the presence of novobiocin [48] . The coumarins have also been shown to inhibit the activity of purifor resistance to clerocidin were cross-resistant to quinolones. Plasmid-encoded gyrA / complemented both quinolone and fied topoisomerase IV, albeit at concentrations higher than those inhibiting DNA gyrase [39, 49] , but the role of topoisomclerocidin resistance in these latter mutants, suggesting that the clerocidin-selected resistant mutants also had alterations erase IV in coumarin action in vivo has not been shown by identification of resistance mutations in the genes for topoisomin GyrA [60] . Terpenoids, however, also inhibit eukaryotic topoisomerase II, thus producing toxicities that have limited erase IV. Novobiocin was developed for clinical use, but its application was limited by adverse effects in patients.
their potential as antibacterial agents but have led to their evaluation as antitumor agents [61, 62] . Other natural products have also been shown to inhibit the ATPase activity of DNA gyrase. In particular, cyclothialidine
Higher bacteria and fungi are well-known producers of antibiotics that act on a range of bacterial targets, including, as and its structural congeners GR122222X, Ro 47-5990, and Ro 48-2865, which are peptide-cyclic lactone derivatives produced indicated above, DNA gyrase. In addition, peptides produced by E. coli plasmids have been shown to act on DNA gyrase. by Streptomyces species [50 -53] , appear to bind to the GyrB protein differently from the coumarins in that some mutations Microcin B17, a product of the mcbA gene encoded on plasmid pMccB17, is a small excreted peptide of 43 amino acids, 14 in gyrB that confer coumarin resistance do not affect the activity of the cyclothialidines [52, 53] . Conversely, some cyclothiaof which are modified after translation to form oxazoles and thiazoles that are condensed into aromatic heterocyclic rings lidine-resistant gyrB mutants of Staphylococcus aureus do not exhibit resistance to coumarins [52] .
[63]. Microcin B17 is taken up by specific pathways in susceptible bacteria [64] and inhibits DNA synthesis by stabilizing a Both the coumarins and the cyclothialidines function as inhibitors of the catalytic functions of DNA gyrase that are decleavage complex with DNA gyrase and DNA [65, 66] . Microcin B17 -resistance mutations have been identified in pendent on ATP hydrolysis (i.e., DNA supercoiling and decatenation), by competitive inhibition of ATP binding.
gyrB as well as in ompF and sbmA, which encode, respectively, outer and inner membrane proteins involved in microcin transCyclothialidines, coumarins, and ATP have been shown to have distinct but overlapping binding sites on a 24-kD N-terminal port. The alteration in GyrB that causes microcin resistance (tryptophan 751 in the carboxy terminal region is changed to GyrB fragment, which has been analyzed by x-ray crystallography [44] . The antibacterial activity of some cyclothialidines arginine) is different from GyrB mutations that cause resistance to coumarins or quinolones, suggesting that the interaction of has been limited by apparently poor permeation into the bacterial cell [51] . microcin B17 with DNA gyrase differs from those of the other classes of agents. Additional genes on plasmid pMccB17 confer Cinodine, a glycocinnamoylspermidine antibiotic produced by a member of the genus Nocardia, binds to DNA and inhibits immunity of the host bacterium to microcin B17 by unknown mechanisms [64, 67] . DNA gyrase but not other DNA binding enzymes in vitro. Its presumed target in vivo is DNA gyrase [54], but cinodine-A second plasmid-encoded polypeptide that targets DNA gyrase in E. coli is the CcdB (LetD) protein encoded by the resistant gyrA or gyrB mutants have not been described.
Flavone compounds, which have multi-ring planar structures F-plasmid. CcdB, in contrast to microcin B17, is larger (11.7 kD vs. 3 kD molecular mass) [68] , is not excreted, and funcsomewhat like the quinolones, also inhibit DNA gyrase supercoiling activity and induce enzyme-dependent DNA cleavtions to ensure the maintenance of the low-copy-number Fplasmid within the cell. CcdB, like microcin B17, stabilizes a age [55] . Competition by flavones for binding of the quinolone norfloxacin to the purified gyrase-DNA complex did not correcleavage complex between DNA gyrase and DNA [68, 69] . The F-plasmid coordinately produces CcdB and CcdA, an ''anlate with potency of these flavones against DNA gyrase, suggesting that the sites of binding of quinolones and flavones tidote'' protein that complexes with CcdB and reverses its binding to GyrA [68, 70] . to the gyrase-DNA complex differed. Recently, some flavone / 9c54$$au23 07-21-98 10:53:13 cida UC: CID S57 CID 1998;27 (Suppl 1)
Bacterial Topoisomerases
For cells that have spontaneously lost the F-plasmid, the resistance by mechanisms other than alterations in topoisomerases will not be covered in this review. protease-dependent decay of CcdA is more rapid than that of CcdB [71] , resulting in the presence of CcdB without CcdA and the consequent killing of plasmid-free segregants. Among
Role of DNA Gyrase in Quinolone Action and Resistance E. coli mutants that are tolerant to the action of CcdB [72, 73] , some map in gyrA, encoding a change from glycine to glutamic Alterations in the GyrA subunit that cause resistance to quinolones have been most extensively studied in E. coli and have acid at position 214 [73] , a change not reported for quinoloneresistant gyrA mutants. Thus, CcdB also appears to interact been increasingly evaluated in quinolone-resistant clinical isolates in many other species as well (reviewed in [86] and uniquely with DNA gyrase.
However, it is the quinolone class of topoisomerase-targeted [87] ). Quinolone-resistance mutations in GyrA have all been localized to the amino terminus between amino acids 67 and compounds, a class of synthetic compounds, that has been developed most extensively for antibacterial therapy. Nalidixic 106, with the most common sites being alterations at positions 83 and 87 (E. coli numbering). Dual mutations in gyrA have acid, which contains a naphthyridine ring structure related to the quinolone ring, was the first member of the class and was been found in some clinical isolates, generally those with higher levels of resistance [88 -91] . identified by Lesher et al. [74] as a byproduct of chloroquine synthesis. The development of nalidixic acid as an antibacterial Alterations in GyrB also cause quinolone resistance, but only two mutations, at positions 426 and 447, have been identified agent preceded by over a decade the discovery of DNA gyrase and the recognition that this enzyme was a drug target in in E. coli [92 -94] . A third mutation at position 463 in GyrB has also been noted in a resistant isolate of Salmonella typhimu-E. coli [29, 75, 76] .
Thousands of quinolone derivatives have been synthesized rium [95] . The changes in amino acid charge of the E. coli GyrB mutations and their effects on resistance to quinolones and screened by many pharmaceutical companies since the original discovery of Lesher et al., and from these efforts have with differing substituents at position 7 of the quinolone nucleus (positively charged piperazine substituents in ciprofloxaemerged and continue to emerge successive generations of potent antibacterial agents that have had broad clinical application cin, ofloxacin, and norfloxacin and other new quinolones and the uncharged methyl substituent of nalidixic acid) have sug- [77, 78] . Just as recognition of DNA gyrase as a drug target lagged behind clinical use, so too has it only recently been gested that there might be a direct electrostatic interaction between the charged amino acid residues and quinolones in the recognized that topoisomerase IV is an additional important target of quinolone antibacterials [40, 79, 80] .
gyrase-DNA complex [93] . This model has been called into question, however, by recent findings regarding the crystal structure of yeast topoisomerase II, which contains domains homologous to the subunits of DNA Quinolones Inhibit Two Topoisomerases gyrase and topoisomerase IV and is discussed in more detail below [96] . GyrB mutations causing quinolone resistance are Quinolones bind to a complex of DNA and DNA gyrase and trap an enzyme-reaction intermediate referred to as a covalent in or near a conserved region, PLRGKMLNV, represented in the yeast structure on a loop between Bb3 and Ba3 that is cleavage (or cleavable) complex in which each DNA strand is covalently linked to the active-site tyrosine at position 122 distant from the catalytic Tyr and the Aa4 helix, which contains homologs of amino acids involved in resistance mediated (Tyr122) of the GyrA subunit [26, 81, 82] . DNA cleavage is detected when the cleavable complex is disrupted by treatment by alterations in GyrA and which is postulated to represent part of a drug-binding site. with protein denaturants. Formation of the cleavable complex rapidly blocks DNA replication, triggers the SOS response, Resistance caused by alterations in GyrA correlates with reduced binding of quinolones to the resistant mutant enzymeand sets in motion subsequent (as yet poorly defined) events that apparently require RNA and protein synthesis and ulti-DNA complexes [97, 98] . Minimal binding occurs to either mutant or wild-type DNA gyrase alone. A 64-kD fragment of mately result in cell death (reviewed in [83] ).
Quinolone-induced gyrase-DNA complexes also form a barGyrA in which the active site Tyr122 is replaced by serine can, when complexed with GyrB, bind DNA but is inactive in rier to movement of RNA polymerase [84] . More recently recognized is the ability of quinolones to inhibit both the DNA quinolone-induced DNA cleavage.
Complexes of GyrA (Ser122), GyrB, and DNA, however, decatenation and relaxation activities of topoisomerase IV and to induce a covalent cleavage complex between this enzyme are still capable of binding ciprofloxacin, suggesting that DNA cleavage is not a requirement for drug binding [99] . The ability and DNA [8, 39, 40, 49, 79, 80, 85] . The relative roles of DNA gyrase and topoisomerase IV in quinolone action will be of one quinolone to displace another bound to the wild-type gyrase -DNA complex correlates with antibacterial potency discussed in the next section, in which the genetic data on quinolone resistance mechanisms involving topoisomerases are [55, 98] . It is interesting that the higher potency of the L enantiomer of ofloxacin (levofloxacin), in comparison with that discussed. These data provide clear evidence that topoisomerase IV, as well as DNA gyrase, is a quinolone target. Quinolone of the R enantiomer, is not reflected by higher affinity but by Full understanding of the sites in the gyrase-DNA complex the gyrase-DNA complex in the proposed initial conformation with the GyrA subunits (and Tyr122) in proximity to one anto which quinolones bind and how the mutant enzyme effects resistance await more detailed structural data. Encouraging other and in position for DNA cleavage. In this context, it is noteworthy that in studies of the gyrase-DNA complex with progress has been made, however, in defining the sites of coumarin and cyclothialidine binding on GyrB, as noted above use of electric dichroism, ATP-induced conformational changes were blocked by norfloxacin [111] , perhaps reflecting a [44, 45, 101, 102] , and more recently in defining the x-ray crystallographic structure of a 92-kD fragment of yeast topotrapped initial conformation in which subsequent ATP-induced conformational changes are blocked. isomerase II, which has homology to DNA gyrase and topoisomerase IV [96] . The B (amino-terminal) domain of topoGenetic data demonstrating that alterations in GyrA or GyrB are alone sufficient to cause quinolone resistance argue that isomerase II is homologous to GyrB and ParE, and the A (carboxy-terminal) domain is homologous to GyrA and ParC.
DNA gyrase is a primary target of the quinolones in vivo. Many studies of this type have clearly shown that DNA gyrase DNA gyrase and topoisomerase IV function as tetramers (Gyr-B 2 GyrA 2 and ParC 2 ParE 2 , respectively), whereas the yeast enis the primary target of many quinolones in E. coli. In other species, the occurrence of single, first-step resistance mutations zyme functions as a homodimer.
There also appear to be additional functional similarities in GyrA also suggests that DNA gyrase is the primary target.
In complementation tests, which are widely used, the domibetween the yeast and bacterial enzymes, since the B domain of topoisomerase II together with GyrA can cleave DNA [96] nance of gyrA / or gyrB / over quinolone-resistant alleles of gyrA and gyrB, respectively, is exploited by introduction of and since some quinolone congeners (e.g., CP-115,953) inhibit the activity of and enhance DNA cleavage by eukaryotic topoplasmid-encoded gyr / genes. Reduction in resistance by introduction of plasmids expressisomerase II (reviewed in [103] ).
X-ray crystallographic structural and other data [104 -106] ing gyr / genes can demonstrate a contribution of altered DNA gyrase to the level of quinolone resistance, but these findings have led to a two-gate model of type II topoisomerase function. In this model the enzyme has two sets of jaws at opposite do not definitively indicate the level of resistance attributable to alterations in DNA gyrase. Because in E. coli the parC and ends of the molecule, connected by multiple joints. One DNA segment (the G or ''gate'' segment) binds the enzyme, inducparE mutations have no resistance phenotype in the absence of a gyrA mutation, plasmid-encoded gyrA / may complement ing a conformational change that brings the A domains together, with movement of the active-site tyrosines into ''atthe cumulative resistance of both gyrA and parC or parE mutations [112] . tack'' position. The second DNA segment (the T or transported segment) is then captured in the open jaws of Similarly, gyrA / complementation cannot be definitively interpreted as evidence that DNA gyrase is a primary drug target, the B domain of the enzyme. Binding of ATP results in dimerization of the B domains with closure of these jaws since mutations in secondary drug targets may be at least partially complemented by plasmid-encoded wild-type alleles and sets in motion a cascade of other conformational changes that result in G-segment cleavage and passage of the T-seg-(specific examples are discussed below) [40, 113] . These distinctions become particularly important with the recent recogniment through the broken G-segment DNA gate.
Reapproximation of the A-A dimer interface with religation that topoisomerase IV is also a target of quinolones. For other species of gram-negative and several other nontion of the G-segment then results in the conformational changes that open the A jaws, allowing exit of the T-segment.
gram-positive bacteria, data also suggest that DNA gyrase is the primary target of quinolones. Proof that DNA gyrase is ATP hydrolysis and release of adenosine diphosphate result in resetting of the enzyme to its initial conformation [96] . This the principal quinolone target, on the basis of genetic demonstration that gyr mutations alone cause resistance, is available model requires substantial sequential movements of several enzyme domains during DNA passage [2] .
for Helicobacter pylori [114] in addition to E. coli. Strongly supportive of the role of DNA gyrase as a primary quinolone If this model of yeast topoisomerase II action can be extended to DNA gyrase and topoisomerase IV, then quinolone target are the findings of gyrA mutations or resistant purified enzyme in first-step resistant mutants of Pseudomonas aerugistabilization of a cleaved gyrase-DNA complex suggests interruption or trapping of the enzyme in a conformation in nosa [115] , Serratia marcescens [116] , Campylobacter jejuni [117, 118] , Coxiella burnetii [119] , and Mycobacterium smegwhich the T segment is cleaved or cleavable, but cleavage itself has been shown not to be required for drug binding matis [120] .
For Neisseria gonorrhoeae [121 -123] , the occurrence of [99] . Drug binding to the topoisomerase IV-DNA complex also alters conformation of DNA in the absence of DNA gyrA mutations in isolates with low-level resistance and both gyrA and parC mutations in isolates with higher levels of resiscleavage [107] .
Furthermore, since ATP does not affect the degree of quinotance mimics the pattern seen in E. coli. Bacterial Topoisomerases encoded gyrA / or gyrB / in some strains supports DNA gyrase created by the cleavage complex before a lethal lesion is generated upon passage of a replication fork. as a primary target, but the level of resistance complemented cannot necessarily be attributed to alterations in DNA gyrase Additional support for this concept was also taken from the observation that the interaction of norfloxacin with DNA gyrase alone [112] .
is bactericidal and the interaction with topoisomerase IV is bacteriostatic [40] . However, this distinction may not apply to Role of Topoisomerase IV in Quinolone Action and all quinolones, since ciprofloxacin kills E. coli gyrA mutants, Resistance and this killing is eliminated with an additional parC mutation [85] . Ciprofloxacin also kills S. aureus by interaction with Purified E. coli topoisomerase IV is also inhibited by quinolones but at concentrations twofold to 10-fold above those topoisomerase IV [79] , as discussed below. In contrast to the findings in E. coli, in staphylococci and inhibiting E. coli DNA gyrase [39, 40, 49] . Quinoloneresistance mutations have now been found in highly conserved other gram-positive bacteria that have been studied, it appears that DNA gyrase is only a secondary target of fluoroquinolones regions of parC [40] and parE [112, 113] that are homologous to those regions in gyrA and gyrB, respectively, in which quinoand that topoisomerase IV is the primary target. Mutations in gyrA are found principally in more highly resistant clinical lone-resistance mutations occur. In both cases parC and parE mutations contribute to quinolone resistance but only in the strains of S. aureus that also have mutations in parC (referred to as grlA in S. aureus) [80] , and parC mutations precede presence of gyrA mutations; parC and parE mutations cause no resistance in strains with wild-type DNA gyrase. For clinical gyrA mutations in single-step resistance selections [125] . The originally described flqA quinolone-resistance locus [126], isolates of E. coli and N. gonorrhoeae, similar parC mutations have been found in highly resistant isolates that also have gyrA which was identified in 14 of 14 single-step mutants of S. aureus independently selected with ciprofloxacin or ofloxamutations.
These data clearly indicate for E. coli and suggest for cin and which is sufficient alone to cause quinolone resistance, is a mutant allele of parC [79] . N. gonorrhoeae that topoisomerase IV is a secondary target for quinolones. These data could be explained if E. coli topoSimilar mutant parC alleles cloned on a plasmid have been shown to confer resistance when transfered into a susceptible isomerase IV is intrinsically more resistant to current quinolones than is DNA gyrase, or if the consequences of quinolone strain of S. aureus [127] . In addition, quinolone-resistance gyrA mutations in S. aureus are silent in the absence of parC mutations action on topoisomerase IV differed from those on DNA gyrase. Because of reported disparities in the magnitude of the [79, 127] . Thus, these genetic data make clear that in S. aureus topoisomerase IV is the primary target of quinolones such as differences in quinolone susceptibility of the two purified enzymes [39, 40, 49] , it is not yet clear if these differences in ciprofloxacin. This difference appears to result from the greater susceptibility to these fluoroquinolones of purified S. aureus topovitro are sufficient to explain the differences in intact bacteria.
However, there are additional data suggesting that the conseisomerase IV relative to purified S. aureus DNA gyrase [128] . In S. aureus, wild-type gyrA / alleles are dominant to resisquences of quinolone interactions with the two enzymes differ. In contrast to the recessive nature of gyrA and gyrB quinolonetant alleles, as they are in E. coli [92] . Thus, positive complementation tests cannot be used as evidence that the compleresistance mutations in merodiploid cells, quinolone-resistant mutant parC and parE are codominant with their respective mented gene encodes a topoisomerase that is the primary drug target. In contrast, resistant alleles of S. aureus parC are domiwild-type alleles [40, 113] . Thus, in E. coli exposed to quinolones, the presence of a wild-type DNA gyrase results in cell nant to the wild-type parC / allele, regardless of whether the resistant allele is located on a plasmid or the chromosome. death even when a resistant DNA gyrase is also present. In contrast, in a cell with a resistant DNA gyrase when both Plasmid-encoded parC / and parE / (termed grlB / in S. aureus) genes together, however, reduce the resistance of mutant chroresistant and susceptible forms of topoisomerase IV are both present, the susceptibility of cells is intermediate between that mosomal parC [127] . These findings suggest that there may be preferential association of the ParE / subunit with the plasmidcaused by each of the two forms of topoisomerase IV alone, a phenomenon referred to as codominance.
encoded ParC subunit (resistant or susceptible) in such a way that the larger amount of plasmid-encoded topoisomerase IV One hypothesis to explain these differences, suggested by Khodursky et al. [40] , is that quinolone-induced DNA cleavage determines the resistance phenotype. In any case, it is clear that the consequences of the interformed with DNA gyrase -DNA complexes, which are located near DNA replication forks, is rapidly converted to lethal DNA actions of quinolones differ between topoisomerase IV and DNA gyrase in S. aureus, as they do in E. coli. For E. coli, it lesions with passage of the replication fork. In contrast, DNA lesions induced by quinolone interactions with the topoisomerhas been suggested that quinolone action on topoisomerase IV is bacteriostatic and quinolone action on DNA gyrase is ase IV -DNA complex, which may be located near the terminus of DNA replication or at least more widely distributed sites on bactericidal, as a possible consequence of the differing opportunities to repair lesions induced by quinolone interaction with the chromosome [85] , only encounter a replication fork after a lag; this allows an opportunity for repair of the initial lesion the two target enzymes [40] . Although quinolone actions on 
